A one-pot Suzuki-hydrogenolysis protocol for the modular synthesis of 2,5-diaryltetrazoles by Livingstone, Keith et al.
One-Pot Suzuki-Hydrogenolysis Protocol for the Modular Synthesis
of 2,5-Diaryltetrazoles
Keith Livingstone, Sophie Bertrand, and Craig Jamieson*
Cite This: https://dx.doi.org/10.1021/acs.joc.0c00807 Read Online
ACCESS Metrics & More Article Recommendations *sı Supporting Information
ABSTRACT: 2,5-Diaryltetrazoles are a diverse range of compounds of
considerable interest within the field of photochemistry as a valuable
precursor of the nitrile imine 1,3-dipole. Current literature approaches
toward this heterocycle remain unsuitable for the practical synthesis of a
library of these derivatives. Herein, we disclose the development of a
modular approach toward 2,5-diaryltetrazoles compatible with an array-
type protocol, facilitated by a tandem Suzuki-hydrogenolysis approach.
■ INTRODUCTION
The recent resurgence of photochemistry as a unique and
powerful method of forging and manipulating C−C bonds has
stimulated the development and adaption of numerous
synthetic protocols.1 One such transformation is the photolysis
of the 2,5-diaryltetrazole moiety to yield the versatile nitrile
imine 1,3-dipole (Scheme 1a).2−4 Owing to its facile reactivity
with a number of functional groups including alkenes4b,5 and
carboxylic acids,6 the nitrile imine has recently found
widespread application in fields where an orthogonal reactivity
profile (click chemistry7) is desirable, such as materials
chemistry and chemical biology.8,9
Due to the traceless reaction profile and inherent simplicity
of photolyzing tetrazole systems, this protocol has become the
most common method of nitrile imine generation. However,
synthetic approaches toward 2,5-tetrazoles are limited relative
to the requirement for structural diversity from the
corresponding dipole precursors. In our laboratories, we were
interested in the synthesis of a small library of 2,5-
diaryltetrazoles10 and were surprised to find that the majority
of recent reports on the preparation of these compounds rely
on a cycloaddition-mediated approach reported by Kakehi
(Scheme 1b) over 40 years ago.11 While this robust synthesis is
compatible with a range of substrates, it also typically employs
hazardous reagents and often laborious purification protocols.
An alternative approach was introduced by Liu in 2015;
however, this route is somewhat limited by the commercial
availability of the requisite aryl amidines.12 The continuing
limitation in the synthesis of these heterocycles appears to be
simultaneous modification of both the N- and C-aryl rings of
the tetrazole. Multiple procedures for the diversification of 5-
aryltetrazoles with a palette of N-aryl groups have been
developed;13 however, modification of the C-aryl ring itself is
primarily restricted to classical syntheses via cycloaddition
between the relevant benzonitrile and hydrazoic acid (Scheme
1b).14 This approach again requires use of toxic and explosive
reagents. More recently, Kamenecka disclosed a route toward
2-aryl-5-bromotetrazoles; however, this also requires the use of
hazardous reagents, and subsequent derivatization to furnish
C-aryl functionalized systems was not conducted.15
While the existing approaches are well-suited to the focused
synthesis of specific 2,5-diaryltetrazole species, we found most
methods incompatible with an array-type approach toward a
library of such compounds. We envisioned that a common
intermediate containing the preformed tetrazole nucleus
encoded with chemoselective functional handles would allow
for simple, rapid modification of both the 2- and 5-positions of
the heterocyclic ring system.
The use of 1-benzyl-5-bromotetrazole (1) as a starting
material fulfilled all of the requirements discussed above for a
facile and robust synthesis of tetrazole systems ready for
further functionalization (Scheme 1c). Given our laboratory’s
previous efforts in the development of a tandem Suzuki-
hydrogenation protocol in the synthesis of sp3-rich pharma-
ceutical building-blocks,16 we reasoned that the treatment of 1
to similar conditions would facilitate modification of the 5-
position, while simultaneously unmasking the 2-position for
derivatization using existing literature methodology.13c Fur-
thermore, 1 itself could be easily accessed on scale by
alkylation and bromination of 1H-tetrazole, a commodity
precursor, obviating the need for the hazardous synthesis of the
heterocyclic constituent.
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■ RESULTS AND DISCUSSION
The current study commenced with the investigation of the
initial Suzuki coupling between 1 and aryl boronic acids. An
initial literature search identified conditions reported by Yi in
the coupling of similar substrates, using Pd(PPh3)4 as a
catalyst.17 As the presence of the triphenylphoshine ligand has
previously been shown to be detrimental in one-pot Suzuki-
hydrogenation methodology,16 we sought to identify a suitable
replacement Pd complex. Our optimization campaign began
with the screening of six palladium precatalysts in combination
with a number of different solvents and bases (Figure 1).
XPhos Pd G3 was quickly identified as a potential alternative
catalyst. When employed in conjunction with toluene, these
reaction conditions afforded a substantially greater conversion
than all other combinations examined.
Gratifyingly, a direct comparison between the previously
reported conditions and this emerging approach furnished
nearly identical yields (Table 1, entries 1 and 2). Furthermore,
this was accomplished over a much shorter time frame of 3 h;
however, the catalyst loading remained higher. Both electron-
donating and mildly electron-deficient boronic acids were
shown to be compatible substrates (Table 1, entries 3 and 4);
however, 4-cyanophenylboronic acid proved recalcitrant to
product formation (Table 1, entry 5). In an effort to determine
the compatibility of strongly electron-deficient boron species
within the reaction manifold, a second screening effort was
conducted, using an array of relevant variables selected based
on the results of the initial screen (Figure 2). These results
suggested that while the nitrile derivative remained intolerant
to the reaction conditions, the improved performance of 4-
(trifluoromethyl)-phenylboronic acid indicated that this issue
was substrate-specific, rather than a consequence of electronic
factors. Throughout this additional screen, XPhos was again
shown to represent the most favorable precatalyst, while
cesium was identified as the carbonate counterion.
With optimal discrete variables in hand, we turned our
attention to the catalyst loading. Preliminary efforts proved
frustrating, with a significant decrease in yield observed upon
reduction of catalyst loading (Table 2, entries 1−3). However,
a concurrent Design of Experiments study18,19 highlighted an
unanticipated correlation between the water stoichiometry of
the reaction, relative to the overall concentration, and the
Scheme 1. (a) Application of 2,5-Tetrazoles as a Nitrile Imine Source; (b) Previous Efforts toward the Synthesis of
Functionalized Tetrazoles; (c) This Work: Modular Synthesis of 2,5-Diaryltetrazoles via a Two-Step Tandem Pd and Cu
Catalysis Approach
Figure 1. Initial catalyst screening identified XPhos Pd G3 as a
suitable candidate for further study. a Conversion was determined by
HPLC with reference to an internal standard. All reactions were
performed on a 2.5 μmol scale using 1.5 equiv of PhB(OH)2, 2 equiv
of base, and a 4:1 solvent/H2O ratio (0.8 M).
Table 1. Direct Comparison between Established Literature
Precedent and the Newly Identified Reaction Conditions
entry R1 conditions
isolated
yield (%)
1a Ph Pd(PPh3)4 (3 mol %), Na2CO3, PhMe,
EtOH, H2O, 110 °C, 16 h
17
75
2b Ph XPhos Pd G3 (10 mol %), K2CO3,
PhMe, H2O, 100 °C, 3 h
76
3b 4-(MeO)
PhB(OH)2
as above 72
4b 4-(F)
PhB(OH)2
as above 60
5b 4-(NC)
PhB(OH)2
as above trace
aPerformed on a 1 mmol scale using 1.3 equiv of PhB(OH)2, 2 equiv
of Na2CO3, and 50 equiv of H2O at a concentration of 0.1 M.
bPerformed on a 0.25 mmol scale using 1.5 equiv of PhB(OH)2, 2
equiv of K2CO3, and 100 equiv of H2O at a concentration of 0.1 M.
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observed conversion (Figure 3, see the Supporting Information
for full details). Exploiting this finding successfully furnished
the optimized reaction conditions for the Suzuki component of
the proposed process, with a catalyst loading of 3 mol %
(Table 2, entries 4−9).
Studies into the subsequent debenzylation protocol proved
to be more straightforward. A screen of eight Pd/C catalysts
from three different sources afforded in many cases examples
of quantitative conversion, with ethanol identified as an
appropriate solvent (Figure 4). Further investigations high-
lighted Evonik’s Noblyst P1071 Pd/C catalyst as a desirable
option to mediate the transformation (see the Supporting
Information for further details). A final optimization found that
a 2.5 mol % loading of catalyst facilitated quantitative
conversion under only 4 bar of hydrogen gas (Table 3, entries
1−3). It was also determined that gentle heating of the
reaction mixture to 40 °C was essential for enabling full
conversion (Table 3, entry 4).
Translation of this methodology into a one-pot procedure
proved challenging, with preliminary attempts affording only
moderate turnover. Gratifyingly, further reducing the pressure
of hydrogen gas was found to increase this yield to
synthetically useful levels (Table 4, entries 1 and 2).
Consistent with our previous work,16 the catalyst ratio was
found to be a crucial factor in maximizing product formation.
While the isolated debenzylation conditions required only a 2.5
mol % Pd/C loading, any reduction below 10% Pd/C
significantly impacted conversion within the one-pot manifold
(Table 4, entry 3). Attempts to circumvent the addition of
ethanol as a cosolvent at the midpoint of the reaction also
failed to furnish improved conversions (Table 4, entries 4−6).
However, satisfactory conditions were identified with a total
Pd catalyst loading of 13 mol %, furnishing a 65% isolated yield
of 3a in 22 h.
With fully optimized reaction conditions in hand, we next
sought to investigate the scope of this one-pot procedure with
respect to the boronic acid substituent (Table 5a).
Figure 2. Additional screen of electron-deficient boron species
indicated that some substrates were compatible with the conditions,
while Cs2CO3 represented a minor improvement over K2CO3.
a
Conversion was determined by LCMS with reference to caffeine as
an internal standard. All reactions were performed on a 50 μmol scale
using 1.5 equiv of PhB(OH)2, 2 equiv of base, and 50 equiv of H2O at
a concentration of 0.1 M.
Table 2. Minimization of Catalyst Loading through
Manipulation of Water Stoichiometrya
entry
catalyst loading
(mol %)
H2O stoichiometry
(equiv)
time
(h)
conversionb
(%)
1 10 10 16 52
2 5 10 16 47
3 2.5 10 16 14
4 10 100 4 70
5 5 100 4 71
6 4 100 4 70
7 3 100 4 71
8 2 100 4 66
9 1 100 4 38
aReactions performed on a 50 μmol scale using 1.3 equiv of
PhB(OH)2 and 1.5 equiv of Cs2CO3 at a concentration of 0.1 M.
bConversion was determined by LCMS with reference to caffeine as
an internal standard.
Figure 3. Response surface from the Design of Experiments study that
revealed the importance of water stoichiometry to conversion through
a secondary correlation with overall reaction concentration. See the
Supporting Information for full details.
Figure 4. Preliminary screening of Pd/C catalysts generated a high
degree of success. (a) Conversions reported as a percentage of the
total peak area of 2a and 3a. All reactions were performed on a 63
μmol scale using 6 bar of H2 and 30 wt % of Pd/C at a concentration
of 0.17 M.
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Introduction of electronically deficient and neutral moieties
were found to be well-tolerated, with minimal impact on yield
(cf. 3b−3d). Similarly, meta- and ortho-substitution of the aryl
component was found to be compatible (cf. 3e and 3f),
although the reduced yield of the meta analogue 3e remains
more difficult to rationalize. More sterically encumbered
substrates 3g and 3h were also successfully isolated. The
modest yield associated with 3h can likely be attributed to the
increased size of the tetrazole hindering adsorption of the
substrate onto the surface of the Pd/C catalyst. Reaction
conditions were also found to be amenable to scale-up, with
substrates 3a, 3b, 3f, and 3g successfully synthesized in good
yield on a 2.5 mmol scale.
While the one-pot generation of 5-aryltetrazoles is preferable
from a practical perspective, the yields of certain substrates
were found to benefit from a directly related two-pot
procedure (Table 5b). This approach enabled the robust
synthesis of electron-rich analogue 3i, a key pharmacophore of
a reported allosteric potentiator of the metabotropic glutamate
2 receptor.20 Vinyl boronic acids were also found to be
compatible, with the synthesis of 3j in good yield, providing
access to alkyl tetrazole derivatives via a formal sp2−sp3
coupling. Biaryl substrates 3k and 3l represent examples of
an important subset of nitrile imine precursors with extended
π-systems with a diminished yield in the case of the bulkier o-
phenyl species. While low-yielding, methoxy ester substrate 3m
provides a valuable functional handle for further derivatization.
To exhibit the versatility of this procedure, the debenzylation
step of this scope exploited the ex situ generation of H2 gas in a
two-chambered reaction vessel known as COware,21 attaining
the required pressure of H2 without the need for more
specialized apparatus.
To further exemplify the advantages afforded by this
modular approach, we targeted the synthesis of a diverse
matrix consisting of 16 2,5-diaryltetrazoles (Table 6). N-Aryl
substituents were selected on the basis of their unique
influence on the properties of the resulting heterocycle, such
as the incorporation of a handle for further covalent
modification (e.g., 4f) or the manipulation of λmax properties
(e.g., 4k). The current approach was found to be highly
effective, with the synthesis of 15 of the 16 tetrazoles
accomplished in good to excellent yields in conjunction with
the established copper-mediated N-arylation protocol.13c The
practicality of this approach represents a significant advance
over existing methods in the synthesis of a diverse library of
nitrile imine precursors. One of the most beneficial aspects is
the absence of time-consuming purification procedures. Owing
to the acidic character of 3, appropriate moderation of pH
during reaction workup afforded all 5-aryl-1H-tetrazoles at a
sufficient level of purity for subsequent manipulation without
the need for additional decontamination. Commencing from 5-
bromotetrazole 1, the synthesis of 2,5-tetrazoles 4a−p required
only one chromatographic purification step prior to the
isolation of the final product. The synthesis of tetrazole 4a
on a 6 mmol also demonstrated the scalability of the
procedure, meaning that the entire route was shown to afford
an overall yield of greater than 50% on a multimillimolar scale.
The unexpected failure of substrate 4j can be perhaps be
attributed to a lower thermal stability of the tetrazole due to
the enhanced push−pull system generated by the substitu-
ents.22
■ CONCLUSIONS
In conclusion, we have developed a convenient and widely
applicable Suzuki-hydrogenolysis protocol enabling the expe-
dient synthesis of 2,5-diaryltetrazoles, valuable precursors of
the nitrile imine 1,3-dipole. The scope of the reaction was
shown to be tolerant of a range of steric and electronic
parameters and was further expanded through the accom-
modation of a hyphenated, two-pot procedure. Facile synthesis
of a diverse palette of 2,5-tetrazoles in combination with
existing Cu-catalyzed methodology has underlined the utility of
this reaction, which offers a complementary means of accessing
the 2,5-diaryltetrazole scaffold in comparison to previous
reports. We intend to further utilize this transformation in our
continued investigations into the reactivity of the pleiotropic
nitrile imine dipole.
■ EXPERIMENTAL SECTION
General Information. All reagents and solvents were obtained
from commercial suppliers and were used without further purification
Table 3. Further Optimization of Hydrogenolysis
Conditions
entry
H2 pressure
(bar)
Pd/C loading
(mol %)
temp
(°C)
conversiond
(%)
1a 6 7 40 97
2b 4 5 40 98
3b 4 2.5 40 99
4c 4 2.5 rt 59
aPerformed on a 63 μmol scale at a concentration of 0.17 M.
bPerformed on a 127 μmol scale at a concentration of 0.17 M.
cPerformed on a 0.3 mmol scale at a concentration of 0.1 M.
dConversions were determined by LCMS with reference to caffeine as
an internal standard.
Table 4. Optimization of One-Pot Reaction Conditionsa
entry
H2
pressure
(bar)
Pd/C
loading
(mol %) solvent
temp
(°C)
conversionb
(%)
1 4 10 PhMec 100 43
2 2 10 PhMec 100 65 (65)d
3 2 5 PhMec 100 34
4 2 10 PhMe 100 24
5 2 10 4:1
PhMe:nBuOH
100 24
6 2 10 4:1
PhMe:EtOH
70 37
aReactions performed on a 0.5 mmol scale using 1.3 equiv of
PhB(OH)2, 1.5 equiv of Cs2CO3, and 100 equiv of H2O at a
concentration of 0.1 M. bConversions were determined by LCMS
with reference to caffeine as an internal standard. cEtOH (2.5 mL)
was added as a cosolvent prior to the hydrogenolysis step of the
reaction. dIsolated yield.
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unless otherwise stated. Purification was carried out according to
standard laboratory methods. All reactions were conducted using
round-bottom flasks or microwave vials of appropriate volume, unless
otherwise stated. Reactions were carried out at elevated temperatures
using a temperature-regulated hot plate/stirrer with a sand bath unless
otherwise stated. Phase separation was conducted using IST Isolute
Phase Separator Cartridges.
Flash chromatography was carried out manually using ZEOprep 60
HYD 40−63 μm silica gel or using a Teledyne ISCO CombiFlashRF+
apparatus with RediSep silica cartridges.
Fourier transform infrared (FTIR) spectra were obtained using a
PerkinElmer Spectrum One Fourier Transform spectrometer with
samples used neat. 1H, 19F, and 13C NMR spectra were obtained on a
Bruker DRX 500, Bruker AVI, or Bruker Nano spectrometer at 400 or
500, 471 or 376, and 100 or 126 MHz, respectively. Chemical shifts
are reported in ppm and coupling constants are reported in Hz with
CDCl3 referenced at 7.26 (
1H) and 77.16 ppm (13C) and DMSO-d6
referenced at 2.50 (1H) and 39.52 ppm (13C). Signal assignment of
novel compounds was instructed using relevant 2D NMR experi-
ments. High-resolution mass spectra were obtained on a Waters
XEVO G2-XS QTof instrument (100−1200 AMU) in positive
ionization mode. Reversed-phase HPLC data was obtained using a
Waters CSH C18 column. LCMS spectra were obtained using an
Acquity UPLC CSH C18 column (50 mm × 2.1 mm i.d. 1.7 μm
packing diameter) at 40 °C. The solvents employed were a 0.1% v/v
solution of formic acid in water and a 0.1% v/v solution of formic acid
in acetonitrile. The UV detection was a summed signal from
wavelengths 210 nm −360 nm. Mass spectral data was acquired using
a Waters QDA instrument (100−1000 AMU at 5 Hz) with an
alternate-scan positive and negative electrospray ionization mode.
HPLC analysis was performed using a gradient method, eluting
with 5−90% MeCN/H2O over 1 min at a flow rate of 1 mL/min
when employing standalone HPLC, and eluting with 3−98% MeCN/
H2O (+ formic acid modifier) over 2 min at a flow rate of 1 mL/min
when used in conjunction with MS. Reactions using an internal
standard required prior HPLC calibration using samples containing
varying molarities of product and caffeine, allowing calculation of the
response factor by substituting values into eq 1. Screening reactions
were then conducted using a known molarity of caffeine internal
standard.
Table 5. (a) Exemplar Scope of Aryl Boronic Acids Compatible with the One-Pot Suzuki-Hydrogenolysis Coupling Protocol;
(b) Library of Boronic Acids Employed as Part of the Hyphenated Two-Pot Synthesis of 5-Aryltetrazoles
aReactions performed on a 0.5 mmol scale using 1.3 equiv of boronic acid, 1.5 equiv of Cs2CO3, and 100 equiv of H2O at a concentration of 0.1 M.
b2.5 mmol scale. c1 equiv of 1, 1.5 equiv of boronic acid, 2 equiv of Cs2CO3, 3 mol % of XPhos Pd G3, and 10 equiv of H2O, heated at 100 °C in a
solution of PhMe (0.2 M) for 2 h. d1 equiv of 3 and 10 mol % of Noblyst Pd/C, heated at 40 °C in a solution of EtOH (0.1M) for 18 h in the
presence of 2 bar H2 generated from Zn and HCl.
eFrom (E)-styrylboronic acid.
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=
( )
( )
response factor
product
standard
area
molarity
area
molarity (1)
General Procedure for the Synthesis of Compounds 3a−3h.
To a 10 mL Biotage Endeavor reaction vessel was added Evonik
Noblyst P1071 20% palladium on carbon (10 mol %). 1-Benzyl-5-
bromo-1H-tetrazole (1, 1 equiv), an aryl boronic acid (1.3 equiv), and
XPhos Pd G3 (3 mol %) were then added as a solution in toluene (0.1
M). To the resulting suspension was added cesium carbonate (1.5
equiv) as a solution in water (100 equiv), at which point the vessel
was purged with nitrogen and stirred at 100 °C for 4 h. Upon cooling
to room temperature, ethanol (50% volume of toluene) was added
before the vessel was placed under a hydrogen atmosphere and heated
at 40 °C for a further 18 h. Upon reaction completion, the mixture
was passed through Celite and partitioned between ethyl acetate (30
mL) and water (30 mL). The organic phase was washed twice more
with water (2 × 30 mL) before the aqueous phases were combined
and acidified using 2 M HCl solution (20 mL). The acidic aqueous
phase was then washed three times with ethyl acetate (3 × 30 mL)
before all organic layers were then combined, passed through a phase
separator, and concentrated under reduced pressure to yield the
product.
General Procedure for the Synthesis of Compounds 3i−3m.
To a microwave vial containing 1-benzyl-5-bromo-1H-tetrazole (1, 1
equiv), an aryl or vinyl boronic acid (1.5 equiv), and XPhos Pd G3 (3
mol %) was added toluene (0.2 M). The vessel was purged with
nitrogen, and cesium carbonate (2 equiv) and water (10 equiv) were
added. The mixture was stirred at 100 °C for 2 h before being cooled
to room temperature. The mixture was diluted with ethyl acetate (10
mL) and passed through a Celite plug, which was then washed with a
further portion of ethyl acetate (10 mL). The solution was
concentrated under reduced pressure and purified by column
chromatography. Isolation of the intermediate 1-benzyl-5-aryltetrazole
was confirmed by 1H NMR spectroscopy before the species was
added to chamber A of a 2 × 10 mL COware reaction vessel21a as a
solution in ethanol (0.1 M). Evonik Noblyst P1071 20% palladium on
carbon (10 mol %) was also added to chamber A, while chamber B
was charged with zinc powder (1.8 mmol, 118 mg) and 36%
hydrogen chloride solution (343 μL, 4 mmol). The vessel was sealed
and stirred at 40 °C for 18 h. The mixture was cooled to room
temperature, diluted with ethyl acetate (10 mL) and passed through a
Celite plug, which was washed with a further portion of ethyl acetate
(10 mL). This organic phase was washed twice with water (2 × 30
mL), before the aqueous phases were combined and acidified using 2
M HCl solution (20 mL). The acidic aqueous phase was then washed
three times with ethyl acetate (3 × 30 mL), before all organic layers
were then combined, passed through a phase separator and
concentrated under reduced pressure to yield the product.
General Procedure for the N-Arylation of 5-aryltetrazoles.
In accordance with previous literature precedent,13c 5-aryltetrazole
(3,1 equiv), an aryl boronic acid (2 equiv), copper(I) oxide (5 mol
%), and DMSO (0.13 M) were added to a microwave vial. The
reaction mixture was stirred under an oxygen atmosphere at 100 °C
for 16 h. The solution was cooled to room temperature and
partitioned between ethyl acetate (20 mL) and 1 M HCl solution (20
mL). The aqueous layer was backwashed with an additional portion of
ethyl acetate (20 mL) before the combined organic layers were
combined, washed with brine (40 mL), passed through a phase
separator and concentrated under reduced pressure. The crude
product was then purified by column chromatography.
Synthesis and Characterization of Compounds 2-4. 1-
Benzyl-5-phenyl-1H-tetrazole (2a). To a microwave vial containing
1-benzyl-5-bromo-1H-tetrazole (60 mg, 0.25 mmol), phenylboronic
acid (45.7 mg, 0.38 mmol), and XPhos Pd G3 (21.2 mg, 0.025 mmol)
was added toluene (2.0 mL). The vessel was purged with nitrogen,
and potassium carbonate (69.1 mg, 0.5 mmol) was added as a
solution in water (0.5 mL). The mixture was stirred at 100 °C for 3 h
before being cooled to room temperature. The mixture was then
diluted with ethyl acetate, passed through Celite, and concentrated
under reduced pressure. The obtained residue was purified by silica
gel column chromatography (12 g silica cartridge, 0−100% EtOAc in
hexane) to give 1-benzyl-5-phenyl-1H-tetrazole (45.2 mg, 0.19 mmol,
76% yield) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.59−
7.52 (m, 3H), 7.51−7.45 (m, 2H), 7.36−7.30 (m, 3H), 7.16−7.11
(m, 2H), 5.61 (s, 2H). 13C{1H} NMR (101 MHz, CDCl3) δ 154.8,
134.0, 131.4, 129.3, 129.2, 128.9, 128.8, 127.3, 123.9, 51.5. HRMS
(ESI) m/z: [M + H]+ calcd for C14H13N4 237.1140, found 237.1142.
IR νmax (neat): 3065, 3033, 2937, 2857, 1529, 1497, 1458, 1401 cm
−1.
Analytical data are in agreement with the literature.17
1-Benzyl-5-(4-fluorophenyl)-1H-tetrazole (2b). To a microwave
vial containing 1-benzyl-5-bromo-1H-tetrazole (60 mg, 0.25 mmol),
(4-fluorophenyl)boronic acid (52.5 mg, 0.38 mmol), and XPhos Pd
G3 (21.2 mg, 0.025 mmol) was added toluene (2.5 mL). The vessel
was purged with nitrogen, and potassium carbonate (69.1 mg, 0.5
mmol) and water (0.045 mL, 2.50 mmol) were added. The mixture
was stirred at 100 °C for 2 h before being cooled to room
temperature. The mixture was then diluted with ethyl acetate, passed
through Celite, and concentrated under reduced pressure. The
obtained residue was purified by silica gel column chromatography
(12 g silica cartridge, 0−100% EtOAc in hexane) to give 1-benzyl-5-
(4-fluorophenyl)-1H-tetrazole (47.9 mg, 0.15 mmol, 60% yield) as a
colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.61−7.54 (m, 2H),
7.37−7.31 (m, 3H), 7.21−7.09 (m, 4H), 5.61 (s, 2H). 19F NMR (376
MHz, CDCl3) δ −107.44 to −107.60 (m). 13C{1H} NMR (101 MHz,
CDCl3) δ 164.6 (d,
1JC−F = 253.2 Hz), 154.0, 133.9, 131.2 (d,
3J C−F =
8.8 Hz), 129.4, 129.0, 127.2, 120.1 (d, 4JC−F = 3.3 Hz), 116.7 (d,
2JC−F
= 22.2 Hz), 51.6. HRMS (ESI) m/z: [M + H] + calcd for
C14H12FN4 255.1046, found 255.1051. IR νmax (neat): 3070, 2964,
2932, 2857, 1606, 1539, 1473, 1450 cm−1. Analytical data are in
agreement with the literature.17
1-Benzyl-5-(4-(trifluoromethyl)phenyl)-1H-tetrazole (2c). To a
microwave vial containing 1-benzyl-5-bromo-1H-tetrazole (60 mg,
0.250 mmol), (4-(trifluoromethyl)phenyl)boronic acid (71.2 mg,
0.375 mmol), and XPhos Pd G3 (10.6 mg, 0.013 mmol) was added
toluene (2.5 mL). The vessel was purged with nitrogen, and cesium
carbonate (163 mg, 0.5 mmol) and water (0.450 mL, 25 mmol) were
Table 6. Synthesis of a Matrix of 2,5-Diaryltetrazoles
Facilitated by Novel Suzuki-Hydrogenolysis Methodologya
aReactions performed on a 0.5 mmol scale using the conditions
described in Table 5a. bReactions performed on a 0.20−0.25 mmol
scale. cN-Arylation was also performed on a 6 mmol scale in an 88%
yield. dOverall yield. eYield of the individual N-arylation step.
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added. The mixture was stirred at 100 °C for 6 h before being cooled
to room temperature. The mixture was then diluted with ethyl acetate,
passed through Celite, and concentrated under reduced pressure. The
obtained residue was purified by silica gel column chromatography
(24 g silica cartridge, 0−100% EtOAc in hexane) to give 1-benzyl-5-
(4-(trifluoromethyl)phenyl)-1H-tetrazole (43.3 mg, 0.14 mmol, 56%
yield) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.77 (d, J =
8.3 Hz, 2H), 7.72 (d, J = 8.2 Hz, 2H), 7.39−7.35 (m, 3H), 7.17−7.13
(m, 2H), 5.64 (s, 2H). 19F NMR (376 MHz, CDCl3) δ −63.17 (s).
13C{1H} NMR (101 MHz, CDCl3) δ 153.7, 133.7, 133.4 (q,
2JC−F =
33.1 Hz), 129.50, 129.45, 129.1, 127.6, 127.2, 126.3 (q, 3JC−F = 3.5
Hz), 123.6 (q, 1JC−F = 272.6 Hz), 51.8. HRMS (ESI) m/z: [M + H]
+
calcd for C15H12F3N4 305.1014, found 305.1018. IR νmax (neat):
3075, 3038, 2964, 1624, 1539, 1497, 1449, 1426 cm−1. Analytical data
are in agreement with the literature.23
1-Benzyl-5-(4-methoxyphenyl)-1H-tetrazole (2i). To a microwave
vial containing 1-benzyl-5-bromo-1H-tetrazole (60 mg, 0.25 mmol),
(4-methoxyphenyl)boronic acid (57.0 mg, 0.38 mmol), and XPhos Pd
G3 (21.2 mg, 0.025 mmol) was added toluene (2.5 mL). The vessel
was purged with nitrogen, and potassium carbonate (69.1 mg, 0.5
mmol) and water (0.045 mL, 2.50 mmol) were added. The mixture
was stirred at 100 °C for 2 h before being cooled to room
temperature. The mixture was then diluted with ethyl acetate, passed
through Celite, and concentrated under reduced pressure. The
obtained residue was purified by silica gel column chromatography
(24 g silica cartridge, 0−100% EtOAc in hexane) to give 1-benzyl-5-
(4-methoxyphenyl)-1H-tetrazole (48.3 mg, 0.18 mmol, 72% yield) as
a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.52 (d, J = 8.0 Hz, 2H),
7.34−7.32 (m, 3H), 7.15−7.13 (m, 2H), 6.98 (d, J = 8.0 Hz, 2H),
5.60 (s, 2H), 3.84 (s, 3H). 13C{1H} NMR (101 MHz, CDCl3) δ
162.0, 154.6, 134.2, 130.5, 129.3, 128.8, 127.2, 115.9, 114.8, 55.6,
51.4. HRMS (ESI) m/z: [M + H]+ calcd for C15H15ON4 267.1246,
found 267.1250. IR νmax (neat): 3081, 3027, 3006, 2958, 2937, 2841,
1611, 1581, 1477, 1446 cm−1. Analytical data are in agreement with
the literature.23
5-Phenyl-1H-tetrazole (3a). Synthesized in accordance with the
general procedure using 1-benzyl-5-bromo-1H-tetrazole (120 mg, 0.5
mmol), phenylboronic acid (79 mg, 0.65 mmol), XPhos Pd G3 (12.7
mg, 15 μmol), Evonik P1071 Pd/C (53.2 mg, 50 μmol), cesium
carbonate (244 mg, 0.75 mmol), water (901 μL, 50 mmol), toluene
(5 mL), and ethanol (2.5 mL) to yield 5-phenyl-1H-tetrazole (47.7
mg, 0.32 mmol, 65% yield) as a white solid.
Synthesized in accordance with the general procedure using 1-
benzyl-5-bromo-1H-tetrazole (598 mg, 2.5 mmol), phenylboronic
acid (396 mg, 3.25 mmol), XPhos Pd G3 (63.5 mg, 75 μmol), Evonik
P1071 Pd/C (266 mg, 250 μmol), cesium carbonate (1220 mg, 3.75
mmol), water (4.50 mL, 250 mmol), toluene (25 mL), and ethanol
(12.5 mL) to yield 5-phenyl-1H-tetrazole (216 mg, 1.48 mmol, 59%
yield) as a white solid. 1H NMR (400 MHz, DMSO) δ 16.84 (br. s,
1H), 8.07−8.01 (m, 2H), 7.64−7.56 (m, 3H). 13C{1H} NMR (101
MHz, DMSO) δ 155.3, 131.2, 129.4, 126.9, 124.1. HRMS (ESI) m/z:
[M + H]+ calcd for C7H7N4 147.0671, found 147.0671. IR νmax
(neat): 3054, 2974, 2911, 2834, 1652, 1608, 1563, 1485, 1465, 1409
cm−1. Analytical data are in agreement with the literature.24
5-(4-Fluorophenyl)-1H-tetrazole (3b). Synthesized in accordance
with the general procedure using 1-benzyl-5-bromo-1H-tetrazole (598
mg, 2.5 mmol), 4-fluorophenylboronic acid (455 mg, 3.25 mmol),
XPhos Pd G3 (63.5 mg, 75 μmol), Evonik P1071 Pd/C (266 mg, 250
μmol), cesium carbonate (1220 mg, 3.75 mmol), water (4.50 mL, 250
mmol), toluene (25 mL), and ethanol (12.5 mL) to yield 5-(4-
fluorophenyl)-1H-tetrazole (245 mg, 1.48 mmol, 59% yield) as a
white solid. 1H NMR (400 MHz, DMSO) δ 16.84 (br. s, 1H), 8.13−
8.06 (m, 2H), 7.46 (app. t, J = 8.9 Hz, 2H). 19F{1H} NMR (376
MHz, DMSO) δ −108.98 (s). 13C{1H} NMR (101 MHz, DMSO) δ
163.6 (d, 1JC−F = 249.0 Hz), 154.8, 129.4 (d,
3JC−F = 9.0 Hz), 120.9,
116.5 (d, 2JC−F = 22.3 Hz). HRMS (ESI)m/z: [M + H]
+ calcd for
C7H6FN4 165.0576, found 165.0579. IR νmax (neat): 3070, 2985,
2916, 2841, 1609, 1498, 1446, 1410 cm−1. Analytical data are in
agreement with the literature.25
5-(4-(Trifluoromethyl)phenyl)-1H-tetrazole (3c). Synthesized in
accordance with the general procedure using 1-benzyl-5-bromo-1H-
tetrazole (120 mg, 0.5 mmol), (4-(trifluoromethyl)phenyl)boronic
acid (123 mg, 0.65 mmol), XPhos Pd G3 (12.7 mg, 15 μmol), Evonik
P1071 Pd/C (53.2 mg, 50 μmol), cesium carbonate (244 mg, 0.75
mmol), water (901 μL, 50 mmol), toluene (5 mL), and ethanol (2.5
mL) to yield 5-(4-(trifluoromethyl)phenyl)-1H-tetrazole (47.1 mg,
0.21 mmol, 42% yield) as a white solid. 1H NMR (400 MHz, DMSO)
δ 17.08 (br. s, 1H), 8.26 (d, J = 7.9 Hz, 2H), 7.98 (d, J = 7.9 Hz, 2H).
19F{1H} NMR (376 MHz, DMSO) δ −61.53 (s). 13C{1H} NMR
(101 MHz, DMSO) δ 155.3, 130.9 (q, 2JC−F = 32.1 Hz), 128.4, 127.7,
126.3, 123.8 (q, 1JC−F = 271.0 Hz). HRMS (ESI) m/z: [M + H]
+
calcd for C8H6F3N4 215.0545, found 215.0547. IR νmax (neat): 3070,
2990, 2916, 2852, 1682, 1573, 1506, 1441 cm−1. Analytical data are in
agreement with the literature.24
5-(p-Tolyl)-1H-tetrazole (3d). Synthesized in accordance with the
general procedure using 1-benzyl-5-bromo-1H-tetrazole (120 mg, 0.5
mmol), p-tolylboronic acid (88 mg, 0.65 mmol), XPhos Pd G3 (12.7
mg, 15 μmol), Evonik P1071 Pd/C (53.2 mg, 50 μmol), cesium
carbonate (244 mg, 0.75 mmol), water (901 μL, 50 mmol), toluene
(5 mL), and ethanol (2.5 mL) to yield 5-(p-tolyl)-1H-tetrazole (41.2
mg, 0.26 mmol, 51% yield) as a white solid. 1H NMR (400 MHz,
DMSO) δ 16.71 (br. s, 1H), 7.96−7.90 (m, 2H), 7.45−7.39 (m, 2H),
2.39 (s, 3H). 13C{1H} NMR (101 MHz, DMSO) δ 141.1, 129.9,
126.8, 121.3, 21.0, 1C not observed. HRMS (ESI) m/z: [M + H]+
calcd for C8H9N4 161.0827, found 161.0828. IR νmax (neat): 3043,
2964, 2917, 2848, 1612, 1570, 1504, 1432, 1404 cm−1. Analytical data
are in agreement with the literature.24
5-(m-Tolyl)-1H-tetrazole (3e). Synthesized in accordance with the
general procedure using 1-benzyl-5-bromo-1H-tetrazole (120 mg, 0.5
mmol), m-tolylboronic acid (88 mg, 0.65 mmol), XPhos Pd G3 (12.7
mg, 15 μmol), Evonik P1071 Pd/C (53.2 mg, 50 μmol), cesium
carbonate (244 mg, 0.75 mmol), water (901 μL, 50 mmol), toluene
(5 mL), and ethanol (2.5 mL) to yield 5-(m-tolyl)-1H-tetrazole (21.3
mg, 0.13 mmol, 26% yield) as a white solid. 1H NMR (400 MHz,
DMSO) δ 16.77 (br. s, 1H), 7.87 (s, 1H), 7.83 (d, J = 7.6 Hz, 1H),
7.48 (t, J = 7.6 Hz, 1H), 7.40 (d, J = 7.6 Hz, 1H), 2.41 (s, 3H).
13C{1H} NMR (101 MHz, DMSO) δ 155.3, 138.8, 131.8, 129.3,
127.4, 124.1, 20.9, 1C not observed. HRMS (ESI) m/z: [M + H]+
calcd for C8H9N4 161.0827, found 161.0828. IR νmax (neat): 3065,
2980, 2918, 2847, 1651, 1599, 1560, 1485, 1456, 1415, 1400, cm−1.
Analytical data are in agreement with the literature.26
5-(o-Tolyl)-1H-tetrazole (3f). Synthesized in accordance with the
general procedure using 1-benzyl-5-bromo-1H-tetrazole (598 mg, 2.5
mmol), o-tolylboronic acid (442 mg, 3.25 mmol), XPhos Pd G3 (63.5
mg, 75 μmol), Evonik P1071 Pd/C (266 mg, 250 μmol), cesium
carbonate (1222 mg, 3.75 mmol), water (4.5 mL, 250 mmol), toluene
(25 mL), and ethanol (12.5 mL) to yield 5-(o-tolyl)-1H-tetrazole
(229 mg, 1.41 mmol, 57% yield) as a white solid. 1H NMR (400
MHz, DMSO) δ 16.63 (br. s, 1H), 7.69 (d, J = 7.6 Hz, 1H), 7.52−
7.36 (m, 3H), 2.48 (s, 3H). 13C{1H} NMR (101 MHz, DMSO) δ
155.2, 137.1, 131.3, 130.7, 129.3, 126.2, 123.8, 20.4. HRMS (ESI) m/
z: [M + H]+ calcd for C8H9N4 161.0827, found 161.0827. IR νmax
(neat): 3065, 3027, 2964, 2921, 2847, 2714, 1654, 1606, 1561, 1484,
1464, 1404 cm−1. Analytical data are in agreement with the
literature.24
5-(Naphthalen-2-yl)-1H-tetrazole (3g). Synthesized in accordance
with the general procedure using 1-benzyl-5-bromo-1H-tetrazole (598
mg, 2.5 mmol), naphthalen-2-ylboronic acid (559 mg, 3.25 mmol),
XPhos Pd G3 (63.5 mg, 75 μmol), Evonik P1071 Pd/C (266 mg, 250
μmol), cesium carbonate (1222 mg, 3.75 mmol), water (4.50 mL, 50
mmol), toluene (25 mL), and ethanol (12.5 mL) to yield 5-
(naphthalen-2-yl)-1H-tetrazole (331 mg, 1.53 mmol, 61% yield) as a
white solid. 1H NMR (400 MHz, DMSO) δ 16.96 (br. s, 1H), 8.66
(d, J = 0.8 Hz, 1H), 8.17−8.07 (m, 3H), 8.05−8.01 (m, 1H), 7.69−
7.61 (m, 2H). 13C{1H} NMR (101 MHz, DMSO) δ 133.9, 132.6,
129.2, 128.6, 127.8, 127.8, 127.2, 126.9, 123.6, 121.6, 1C not
observedHRMS (ESI) m/z: [M + H]+ calcd for C11H9N4 197.0827,
found 197.0831. IR νmax (neat): 3128, 3059, 2990, 2921, 2889, 2841,
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1635, 1609, 1564, 1510, 1417 cm−1. Analytical data are in agreement
with the literature.24
5-(Pyren-1-yl)-1H-tetrazole (3h). Synthesized in accordance with
the general procedure using 1-benzyl-5-bromo-1H-tetrazole (120 mg,
0.5 mmol), pyren-1-ylboronic acid (160 mg, 0.65 mmol), XPhos Pd
G3 (12.7 mg, 15 μmol), Evonik P1071 Pd/C (53.2 mg, 50 μmol),
cesium carbonate (244 mg, 0.75 mmol), water (901 μL, 50 mmol),
toluene (5 mL), and ethanol (2.5 mL) to yield 5-(pyren-1-yl)-1H-
tetrazole (37.6 mg, 0.11 mmol, 23% yield) as a white solid. 1H NMR
(400 MHz, DMSO) δ 17.12 (br. s, 1H), 8.95 (d, J = 9.3 Hz, 1H), 8.49
(s, 2H), 8.44 (d, J = 2.9 Hz, 1H), 8.42 (d, J = 2.9 Hz, 1H), 8.39 (d, J =
9.4 Hz, 1H), 8.36 (d, J = 8.9 Hz, 1H), 8.30 (d, J = 8.9 Hz, 1H), 8.21−
8.15 (m, 1H). 13C{1H} NMR (101 MHz, DMSO) δ 132.5, 130.7,
130.1, 129.2, 129.1, 128.8, 128.5, 128.1, 127.3, 127.2, 126.9, 126.4,
126.1, 125.0, 124.2, 124.0, 123.4. HRMS (ESI) m/z: [M + H]+ calcd
for C17H11N4 271.0984, found 271.0988. IR νmax (neat): 3022, 2921,
2847, 1577, 1454, 1421 cm−1. Analytical data are in agreement with
the literature.27
5-(4-Methoxyphenyl)-1H-tetrazole (3i). Synthesized in accordance
with the general procedure using 1-benzyl-5-bromo-1H-tetrazole (120
mg, 0.5 mmol), 4-methoxyphenylboronic acid (114 mg, 0.75 mmol),
XPhos Pd G3 (12.7 mg, 15 μmol), cesium carbonate (326 mg, 1.0
mmol), water (90 μL, 5.0 mmol), toluene (2.5 mL), Evonik P1071
Pd/C (36.3 mg, 34 μmol), and ethanol (2.5 mL) to yield 5-(4-
methoxyphenyl)-1H-tetrazole (49.4 mg, 0.28 mmol, 60% yield) as a
white solid. 1H NMR (400 MHz, DMSO) δ 7.98 (d, J = 8.9 Hz, 2H),
7.16 (d, J = 8.9 Hz, 2H), 3.84 (s, 3H) 1H not observed
(exchangeable). 13C{1H} NMR (101 MHz, DMSO) δ 161.4, 128.6,
127.0, 116.3, 114.8, 55.4. HRMS (ESI) m/z: [M + H]+ calcd for
C8H9ON4 177.0776, found 177.0770. IR νmax (neat): 3160, 3081,
3022, 2919, 2843, 1610, 1585, 1499, 1470, 1443, 1405 cm−1.
Analytical data are in agreement with the literature.24
5-Phenethyl-1H-tetrazole (3j). Synthesized in accordance with the
general procedure using 1-benzyl-5-bromo-1H-tetrazole (120 mg, 0.5
mmol), (E)-styrylboronic acid (111 mg, 0.75 mmol), XPhos Pd G3
(12.7 mg, 15 μmol), cesium carbonate (326 mg, 1.0 mmol), water (90
μL, 5.0 mmol), toluene (2.5 mL), Evonik P1071 Pd/C (29.6 mg, 28
μmol), and ethanol (2.5 mL) to yield 5-phenethyl-1H-tetrazole (48.9
mg, 0.28 mmol, 77% yield) as a white solid. 1H NMR (500 MHz,
DMSO) δ 11.07 (br. s, 1H), 7.28−7.35 (m, 2H), 7.23−7.15 (m, 3H),
3.18 (t, J = 7.8 Hz, 2H), 3.06 (t, J = 7.7 Hz, 2H). 13C{1H} NMR (126
MHz, DMSO) δ 155.4, 140.0, 128.4, 128.3, 126.3, 32.7, 24.6. HRMS
(ESI) m/z: [M + H]+ calcd for C9H11N4 175.0984, found 175.0977.
IR νmax (neat): 3030, 3007, 2992, 2972, 2922, 2857, 1560, 1491,
1454, 1425, 1408 cm−1. Analytical data are in agreement with the
literature.28
5-([1,1′-Biphenyl]-2-yl)-1H-tetrazole (3k). Synthesized in accord-
ance with the general procedure using 1-benzyl-5-bromo-1H-tetrazole
(120 mg, 0.5 mmol), [1,1′-biphenyl]-2-ylboronic acid (150 mg, 0.75
mmol), XPhos Pd G3 (12.7 mg, 15 μmol), cesium carbonate (326
mg, 1.0 mmol), water (90 μL, 5.0 mmol), toluene (2.5 mL), Evonik
P1071 Pd/C (36.3 mg, 34 μmol), and ethanol (2.5 mL) to yield 5-
([1,1′-biphenyl]-2-yl)-1H-tetrazole (24.1 mg, 0.11 mmol, 22% yield)
as a white solid. Column chromatography (0−100% ethyl acetate in
petroleum ether) following the hydrogenolysis step was required for
this substrate. 1H NMR (400 MHz, DMSO) δ 7.72−7.65 (m, 2H),
7.61−7.54 (m, 2H), 7.34−7.28 (m, 3H), 7.12−7.07 (m, 2H) 1H not
observed (exchangeable). 13C{1H} NMR (101 MHz, DMSO) δ
141.5, 139.2, 131.1, 130.6, 128.7, 128.2, 127.7, 127.4, 123.4, 2C not
observed. HRMS (ESI) m/z: [M + H]+ calcd for C13H11N4 223.0978,
found 223.0979. IR νmax (neat): 3059, 2963, 2918, 2886, 2845, 2822,
1601, 1572, 1560, 1477, 1454, 1437 cm−1. Analytical data are in
agreement with the literature.28
5-([1,1′-Biphenyl]-4-yl)-1H-tetrazole (3l). Synthesized in accord-
ance with the general procedure using 1-benzyl-5-bromo-1H-tetrazole
(120 mg, 0.5 mmol), [1,1′-biphenyl]-4-ylboronic acid (150 mg, 0.75
mmol), XPhos Pd G3 (12.7 mg, 15 μmol), cesium carbonate (326
mg, 1.0 mmol), water (90 μL, 5.0 mmol), toluene (2.5 mL), Evonik
P1071 Pd/C (27.3 mg, 26 μmol), and ethanol (2.5 mL) to yield 5-
([1,1′-biphenyl]-4-yl)-1H-tetrazole (56.7 mg, 0.26 mmol, 53% yield)
as a white solid. 1H NMR (500 MHz, DMSO) δ 8.15 (d, J = 8.3 Hz,
2H), 7.91 (d, J = 8.3 Hz, 2H), 7.76 (d, J = 7.5 Hz, 2H), 7.50 (app. t, J
= 7.6 Hz, 2H), 7.43−7.40 (m, 1H). 13C{1H} NMR (126 MHz,
DMSO) δ 155.0, 151.0, 142.7, 138.9, 129.1, 128.2, 127.6, 126.8,
123.1. HRMS (ESI) m/z: [M + H] calcd for C13H11N4 223.0978,
found 223.0979. IR νmax (neat): 3092, 3059, 3003, 2982, 2922, 2851,
1614, 1560, 1522, 1501, 1483, 1452, 1425 cm−1. Analytical data are in
agreement with the literature.24
Methyl 4-(1H-Tetrazol-5-yl)benzoate (3m). Synthesized in
accordance with the general procedure using 1-benzyl-5-bromo-1H-
tetrazole (120 mg, 0.5 mmol), (4-(methoxycarbonyl)phenyl)boronic
acid (135 mg, 0.75 mmol), XPhos Pd G3 (12.7 mg, 15 μmol), cesium
carbonate (326 mg, 1.0 mmol), water (90 μL, 5.0 mmol), toluene (2.5
mL), Evonik P1071 Pd/C (10.6 mg, 10 μmol), and ethanol (1.5 mL)
to yield methyl 4-(1H-tetrazol-5-yl)benzoate (20.3 mg, 0.10 mmol,
27% yield) as a yellow solid. 1H NMR (400 MHz, DMSO) δ 8.19 (d,
J = 8.6 Hz, 2H), 8.15 (d, J = 8.7 Hz, 2H), 3.89 (s, 3H). 13C{1H}
NMR (101 MHz, DMSO) δ 165.6, 155.7, 145.3, 131.5, 130.1, 127.2,
52.4. HRMS (ESI) m/z: [M + H]+ calcd for C9H9N4O2 205.0720,
found 205.0720. IR νmax (neat): 3154, 3098, 3073, 3046, 3019, 2953,
2928, 2855, 1709, 1686, 1566, 1499, 1427 cm−1. Analytical data are in
agreement with the literature.28
2,5-Diphenyl-2H-tetrazole (4a). Synthesized in accordance with
the general procedure using tetrazole 3a (29 mg, 0.2 mmol),
phenylboronic acid (49 mg, 0.4 mmol), copper(I) oxide (1.4 mg, 10
μmol), and DMSO (2 mL) to yield 2,5-diphenyl-2H-tetrazole (36.7
mg, 0.17 mmol, 83% yield) as a white solid.
Synthesized in accordance with the general procedure using
tetrazole 3a (877 mg, 6.0 mmol), phenylboronic acid (1.5 g, 12
mmol), copper(I) oxide (43 mg, 0.3 mmol), and DMSO (10 mL) to
yield 2,5-diphenyl-2H-tetrazole (1.2 g, 5.3 mmol, 88% yield) as a
white solid. 1H NMR (400 MHz, CDCl3) δ 8.30−8.24 (m, 2H),
8.24−8.18 (m, 2H), 7.62−7.47 (m, 6H). 13C{1H} NMR (101 MHz,
CDCl3) δ 165.4, 137.1, 130.7, 129.8, 129.8, 129.1, 127.3, 127.2, 120.0.
HRMS (ESI) m/z: [M + H]+ calcd for C13H12N4 223.0984, found
223.0986. IR νmax (neat): 3066, 1595, 1530, 1497, 1470, 1447 cm
−1.
Analytical data are in agreement with the literature.29
N-(4-(5-Phenyl-2H-tetrazol-2-yl)phenyl)acetamide (4b). Synthe-
sized in accordance with the general procedure using tetrazole 3a (29
mg, 0.2 mmol), (4-acetamidophenyl)boronic acid (72 mg, 0.4 mmol),
copper(I) oxide (1.4 mg, 10 μmol), and DMSO (2 mL) to yield N-(4-
(5-phenyl-2H-tetrazol-2-yl)phenyl)acetamide (49.7 mg, 0.18 mmol,
83% yield) as a brown solid. 1H NMR (400 MHz, DMSO) δ 10.32 (s,
1H), 8.18−8.13 (m, 2H), 8.09 (d, J = 9.0 Hz, 2H), 7.88 (d, J = 9.0
Hz, 2H), 7.63−7.58 (m, 3H), 2.11 (s, 3H). 13C{1H} NMR (101
MHz, MeOD) δ 162.4, 156.8, 132.3, 124.3, 122.3, 120.7, 118.9, 118.4,
112.1, 112.0, 14.5. HRMS (ESI) m/z: [M + H]+ calcd for C15H14N5O
280.1193, found 280.1196. IR νmax (neat): 3265, 3144, 3073, 2961,
2926, 1667, 1605, 1557, 1531, 1510, 1468, 1452, 1418 cm−1.
Analytical data are in agreement with the literature.29
2-(Naphthalen-2-yl)-5-phenyl-2H-tetrazole (4c). Synthesized in
accordance with the general procedure using tetrazole 3a (29 mg, 0.2
mmol), 2-naphthylboronic acid (69 mg, 0.4 mmol), copper(I) oxide
(1.4 mg, 10 μmol), and DMSO (2 mL) to yield 2-(naphthalen-2-yl)-
5-phenyl-2H-tetrazole (46 mg, 0.17 mmol, 84% yield) as a yellow
solid. 1H NMR (400 MHz, CDCl3) δ 8.65 (d, J = 2.0 Hz, 1H), 8.34−
8.28 (m, 3H), 8.02 (d, J = 8.9 Hz, 1H), 7.98 (dd, J = 6.5, 2.7 Hz, 1H),
7.91 (dd, J = 6.3, 2.9 Hz, 1H), 7.62−7.48 (m, 5H). 13C{1H} NMR
(101 MHz, CDCl3) δ 165.4, 134.4, 133.5, 133.2, 130.7, 130.0, 129.1,
128.8, 128.1, 127.6, 127.5, 127.3, 127.2, 118.3, 118.0. HRMS (ESI)
m/z: [M + H]+ calcd for C17H13N4 273.1140, found 273.1143. IR νmax
(neat): 3067, 3051, 2922, 1599, 1514, 1495, 1472, 1449 cm−1
5-Phenyl-2-(o-tolyl)-2H-tetrazole (4d). Synthesized in accordance
with the general procedure using tetrazole 3a (29 mg, 0.2 mmol), o-
tolylboronic acid (54 mg, 0.4 mmol), copper(I) oxide (1.4 mg, 10
μmol), and DMSO (2 mL) to yield 5-phenyl-2-(o-tolyl)-2H-tetrazole
(37 mg, 0.16 mmol, 78% yield) as an off-white solid. 1H NMR (400
MHz, CDCl3) δ 8.29−8.22 (m, 2H), 7.70−7.65 (m, 1H), 7.57−7.49
(m, 3H), 7.48−7.38 (m, 3H), 2.44 (s, 3H). 13C{1H} NMR (101
MHz, CDCl3) δ 165.1, 136.7, 133.3, 132.1, 130.7, 130.5, 129.1, 127.4,
The Journal of Organic Chemistry pubs.acs.org/joc Article
https://dx.doi.org/10.1021/acs.joc.0c00807
J. Org. Chem. XXXX, XXX, XXX−XXX
H
127.2, 127.1, 125.4, 18.9. HRMS (ESI) m/z: [M + H]+ calcd for
C14H13N4 237.1140, found 237.1141. IR νmax (neat): 3051, 2959,
2920, 2853, 1585, 1530, 1497, 1468, 1450 cm−1. Analytical data are in
agreement with the literature.13c
5-(4-Fluorophenyl)-2-phenyl-2H-tetrazole (4e). Synthesized in
accordance with the general procedure using tetrazole 3b (39 mg,
0.24 mmol), phenylboronic acid (49 mg, 0.48 mmol), copper(I) oxide
(1.7 mg, 12 μmol), and DMSO (2 mL) to yield 5-(4-fluorophenyl)-2-
phenyl-2H-tetrazole (45 mg, 0.19 mmol, 78% yield) as a white solid.
1H NMR (400 MHz, CDCl3) δ 8.28−8.21 (m, 2H), 8.20−8.15 (m,
2H), 7.61−7.54 (m, 2H), 7.53−7.47 (m, 1H), 7.24−7.17 (m, 2H).
19F NMR (471 MHz, CDCl3) δ −109.57 (tt, J = 8.6, 5.3 Hz).
13C{1H} NMR (101 MHz, CDCl3) δ 164.6, 164.4 (d,
1JC‑F = 250.9
Hz), 137.0, 129.9, 129.2 (d, 3JC−F= 8.8 Hz), 123.6 (d,
4JC‑F = 3.1 Hz),
120, 116.2 (d, 2JC‑F = 22.0 Hz). HRMS (ESI) m/z: [M + H]
+ calcd
for C13H10FN4 241.0889, found 241.0891. IR νmax (neat): 3082, 3069,
3045, 3026, 2924, 1597, 1541, 1495, 1491, 1474, 1458, 1423 cm−1.
Analytical data are in agreement with the literature.30
N-(4-(5-(4-Fluorophenyl)-2H-tetrazol-2-yl)phenyl)acetamide
(4f). Synthesized in accordance with the general procedure using
tetrazole 3b (32.8 mg, 0.2 mmol), (4-acetamidophenyl)boronic acid
(71.6 mg, 0.4 mmol), copper(I) oxide (1.4 mg, 12 μmol), and DMSO
(2 mL) to yield N-(4-(5-(4-fluorophenyl)-2H-tetrazol-2-yl)phenyl)-
acetamide (42 mg, 0.14 mmol, 71% yield) as a white solid. 1H NMR
(400 MHz, DMSO) δ 10.31 (s, 1H), 8.20 (dd, J = 8.5, 5.6 Hz, 2H),
8.08 (d, J = 8.9 Hz, 2H), 7.87 (d, J = 8.9 Hz, 2H), 7.45 (app. t, J = 8.8
Hz, 2H), 2.10 (s, 3H). 19F NMR (471 MHz, DMSO) δ −109.54 −
−109.62 (m). 13C{1H} NMR (101 MHz, CDCl3) δ 168.8, 163.6 (d,
1JC‑F = 248.1 Hz), 163.5, 141.0, 131.0, 129.0 (d,
3JC‑F = 8.8 Hz), 123.1
(d, 4JC‑F = 2.9 Hz), 120.7, 119.7, 116.5 (d,
2JC−F = 22.0 Hz), 24.1.
HRMS (ESI) m/z: [M + H]+ calcd for C15H13FN5O 298.1099, found
298.1101. IR νmax (neat): 3310, 3277, 3208, 3150, 3088, 1665, 1609,
1541, 1508, 1466, 1423, 1414 cm−1.
5-(4-Fluorophenyl)-2-(naphthalen-2-yl)-2H-tetrazole (4g). Syn-
thesized in accordance with the general procedure using tetrazole 3b
(39.2 mg, 0.24 mmol), 2-naphthylboronic acid (68.8 mg, 0.42 mmol),
copper(I) oxide (1.7 mg, 12 μmol), and DMSO (2 mL) to yield 5-(4-
fluorophenyl)-2-(naphthalen-2-yl)-2H-tetrazole (10 mg, 0.04 mmol,
15% yield) as a yellow solid. 1H NMR (400 MHz, CDCl3) δ 8.66 (d, J
= 2.0 Hz, 1H), 8.35−8.26 (m, 3H), 8.04 (d, J = 9.0 Hz, 1H), 8.02−
7.98 (m, 1H), 7.96−7.91 (m, 1H), 7.65−7.56 (m, 2H), 7.24 (dd, J =
13.6, 4.9 Hz, 2H). 19F NMR (471 MHz, CDCl3) δ −109.41 to
−109.65 (m). 13C{1H} NMR (101 MHz, CDCl3) δ 164.7, 163.4 (d,
1JC−F = 250.8 Hz), 134.4, 133.6, 133.2, 130.1, 129.3 (d,
3 JC−F = 8.6
Hz), 128.8, 128.2, 127.7, 127.6, 123.6 (d, 4 JC−F = 4.2 Hz), 118.4,
118.0, 116.3 (d, 2J C−F = 22.3 Hz). HRMS (ESI) m/z: [M + H]
+
calcd for C17H12FN4
+ 291.1046, found 291.1046. IR νmax (neat):
3061, 2953, 2922, 2851, 1607, 1603, 1539, 1510, 1476, 1460, 1447,
1423 cm−1.
5-(4-Fluorophenyl)-2-(o-tolyl)-2H-tetrazole (4h). Synthesized in
accordance with the general procedure using tetrazole 3b (32.8 mg,
0.20 mmol), o-tolylboronic acid (54 mg, 0.4 mmol), copper(I) oxide
(1.4 mg, 10 μmol), and DMSO (2 mL) to yield 5-(4-fluorophenyl)-2-
(o-tolyl)-2H-tetrazole (41.4 mg, 0.16 mmol, 81% yield) as an off-
white solid. 1H NMR (400 MHz, CDCl3) δ 8.27−8.21 (m, 2H), 7.66
(dd, J = 7.7, 1.1 Hz, 1H), 7.50−7.37 (m, 3H), 7.25−7.18 (m, 2H),
2.43 (s, 3H). 19F NMR (471 MHz, CDCl3) δ −109.70 (tt, J = 8.6, 5.3
Hz). 13C{1H} NMR (101 MHz, CDCl3) δ 164.33 (d,
1JC−F = 250.7
Hz), 164.31, 136.6, 133.2, 132.1, 130.5, 129.2 (d, 3JC−F = 8.6 Hz),
127.1, 125.4, 123.7 (d, 4JC−F = 2.9 Hz), 116.3 (d,
2JC−F = 22.3 Hz),
18.9. HRMS (ESI) m/z: [M + H]+ calcd for C14H12FN4
+ 255.1046,
found 255.1051. IR νmax (neat): 3088, 2984, 2963, 2924, 2853, 1603,
1497, 1472, 1458, 1423 cm−1
5-(Naphthalen-2-yl)-2-phenyl-2H-tetrazole (4i). Synthesized in
accordance with the general procedure using tetrazole 3g (39.2 mg,
0.20 mmol), phenylboronic acid (49 mg, 0.4 mmol), copper(I) oxide
(1.4 mg, 10 μmol), and DMSO (2 mL) to yield 5-(naphthalen-2-yl)-
2-phenyl-2H-tetrazole (46.4 mg, 0.17 mmol, 85% yield) as a beige
solid. 1H NMR (500 MHz, CDCl3) δ 8.80 (s, 1H), 8.32 (dd, J = 8.5,
1.6 Hz, 1H), 8.26−8.22 (m, 2H), 8.02−7.97 (m, 2H), 7.92−7.87 (m,
1H), 7.61−7.54 (m, 4H), 7.51 (app. t, J = 7.4 Hz, 1H). 13C{1H}
NMR (126 MHz, CDCl3) δ 165.5, 137.1, 134.5, 133.4, 129.81,
129.77, 128.93, 128.87, 128.0, 127.4, 127.1, 126.9, 124.6, 124.1, 120.0.
HRMS (ESI) m/z: [M + H]+ calcd for C17H13N4 273.1140, found
273.1143. IR νmax (neat): 3051, 2930 2853, 1595, 1522, 1503, 1468,
1436 cm−1.
2,5-Di(naphthalen-2-yl)-2H-tetrazole (4k). Synthesized in accord-
ance with the general procedure using tetrazole 3g (39.2 mg, 0.20
mmol), 2-naphthylboronic acid (69 mg, 0.4 mmol), copper(I) oxide
(1.4 mg, 10 μmol), and DMSO (2 mL) to yield 2,5-di(naphthalen-2-
yl)-2H-tetrazole (10.2 mg, 0.03 mmol, 16% yield) as a white solid. 1H
NMR (400 MHz, CDCl3) δ 8.85 (s, 1H), 8.72 (d, J = 1.7 Hz, 1H),
8.39 (dd, J = 4.5, 1.8 Hz, 1H), 8.37 (dd, J = 4.1, 1.8 Hz, 1H), 8.07 (d,
J = 9.0 Hz, 1H), 8.05−7.99 (m, 3H;), 7.97−7.90 (m, 2H;), 7.66−7.55
(m, 4H). 13C{1H} NMR (101 MHz, CDCl3) δ 165.6, 134.6, 134.5,
133.6, 133.4, 133.3, 130.1, 129.0, 128.9, 128.85, 128.2, 128.1, 127.7,
127.6, 127.4, 127.2, 126.9, 124.6, 124.2, 118.5, 118.1. HRMS (ESI)
m/z: [M + H]+ calcd for C21H15N4 323.1297, found 323.1299. IR νmax
(neat): 3055, 3030, 1630, 1603, 1524, 1501, 1474, 1437 cm−1
5-(Naphthalen-2-yl)-2-(o-tolyl)-2H-tetrazole (4l). Synthesized in
accordance with the general procedure using tetrazole 3g (39.2 mg,
0.20 mmol), o-tolylboronic acid (54 mg, 0.4 mmol), copper(I) oxide
(1.4 mg, 10 μmol), and DMSO (2 mL) to yield 5-(naphthalen-2-yl)-
2-(o-tolyl)-2H-tetrazole (20.0 mg, 0.07 mmol, 35% yield) as a beige
solid. 1H NMR (500 MHz, CDCl3) δ 8.80 (s, 1H), 8.32 (dd, J = 8.5,
1.6 Hz, 1H), 8.00 (d, J = 8.5 Hz, 1H), 8.00−7.97 (m, 1H), 7.93−7.88
(m, 1H), 7.71 (d, J = 7.9 Hz, 1H), 7.59−7.53 (m, 2H), 7.51−7.39 (m,
3H), 2.47 (s, 3H). 13C{1H} NMR (126 MHz, CDCl3) δ 165.2, 136.7,
134.5, 133.4, 133.3, 132.1, 130.5, 129.0, 128.9, 128.0, 127.3, 127.07,
127.05, 126.9, 125.4, 124.7, 124.1, 19.0. HRMS (ESI) m/z: [M + H]+
calcd for C18H15N4 287.1297, found 287.1299. IR νmax (neat): 3061,
2924, 2853, 1605, 1522, 1493, 1464, 1435 cm−1
2-Phenyl-5-(o-tolyl)-2H-tetrazole (4m). Synthesized in accordance
with the general procedure using tetrazole 3f (32.0 mg, 0.20 mmol),
phenylboronic acid (49 mg, 0.4 mmol), copper(I) oxide (1.4 mg, 10
μmol), and DMSO (2 mL) to yield 2-phenyl-5-(o-tolyl)-2H-tetrazole
(32.0 mg, 0.14 mmol, 68% yield) as an off-white solid. 1H NMR (400
MHz, DMSO) δ 8.19−8.13 (m, 2H), 8.04 (dd, J = 7.6, 1.2 Hz, 1H),
7.73−7.66 (m, 2H), 7.64−7.59 (m, 1H), 7.50−7.36 (m, 3H), 2.64 (s,
3H). 13C{1H} NMR (101 MHz, DMSO) δ 164.9, 137.0, 136.2, 131.5,
130.4, 130.1, 129.2, 126.3, 125.6, 119.9, 21.2, 1C not observed.
HRMS (ESI) m/z: [M + H]+ calcd for C14H13N4 237.1135, found
237.1134. IR νmax (neat): 3076, 3030, 2980, 2959, 2926, 1595, 1522,
1497, 1479, 1456, 1418 cm−1.
N-(4-(5-(o-Tolyl)-2H-tetrazol-2-yl)phenyl)acetamide (4n). Syn-
thesized in accordance with the general procedure using tetrazole 3f
(32.0 mg, 0.20 mmol), (4-acetamidophenyl)boronic acid (71.6 mg,
0.4 mmol), copper(I) oxide (1.4 mg, 10 μmol), and DMSO (2 mL)
to yield N-(4-(5-(o-tolyl)-2H-tetrazol-2-yl)phenyl)acetamide (41.2
mg, 0.14 mmol, 71% yield) as a white solid. 1H NMR (400 MHz,
CDCl3) δ 8.17−8.13 (m, 2H), 8.13−8.09 (m, 1H), 7.75 (d, J = 8.9
Hz, 2H), 7.56 (br. s, 1H), 7.43−7.31 (m, 3H), 2.71 (s, 3H), 2.23 (s,
3H). 13C{1H} NMR (101 MHz, CDCl3) δ 168.6, 165.7, 139.3, 137.8,
133.0, 131.6, 130.3, 129.7, 126.3, 126.2, 120.7, 120.5, 24.8, 21.9.
HRMS (ESI) m/z: [M + H]+ calcd for C16H16N5O 294.1349, found
294.1351. IR νmax (neat): 3294, 3269, 3211, 3148, 3075, 2957, 2926,
1661, 1611, 1535, 1510, 1481, 1450, 1414 cm−1
2-(Naphthalen-2-yl)-5-(o-tolyl)-2H-tetrazole (4o). Synthesized in
accordance with the general procedure using tetrazole 3f (32.0 mg,
0.20 mmol), 2-naphthylboronic acid (69 mg, 0.4 mmol), copper(I)
oxide (1.4 mg, 10 μmol), and DMSO (2 mL) to yield 2-(naphthalen-
2-yl)-5-(o-tolyl)-2H-tetrazole (17.3 mg, 0.06 mmol, 30% yield) as an
off-white solid. 1H NMR (400 MHz, CDCl3) δ 8.68 (d, J = 2.0 Hz,
1H, 8.35 (dd, J = 9.0, 2.2 Hz, 1H), 8.18 (dd, J = 8.0, 1.5 Hz, 1H), 8.05
(d, J = 9.0 Hz, 1H), 8.03−7.99 (m, 1H), 7.97−7.91 (m, 1H), 7.65−
7.57 (m, 2H), 7.45−7.35 (m, 3H), 2.77 (s, 3H). 13C{1H} NMR (101
MHz, CDCl3) δ 165.9, 137.9, 134.5, 133.5, 133.3, 131.6, 130.3, 130.1,
129.8, 128.8, 128.2, 127.7, 127.5, 126.4, 126.3, 118.3, 118.0, 22.0.
HRMS (ESI) m/z: [M + H]+ calcd for C18H15N4 287.1291, found
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287.1288. IR νmax (neat): 3049, 3034, 2959, 2922, 2851, 1603, 1514,
1474, 1449 cm−1.
2,5-Di-o-tolyl-2H-tetrazole (4p). Synthesized in accordance with
the general procedure using tetrazole 3f (32.0 mg, 0.20 mmol), o-
tolylboronic acid (54 mg, 0.4 mmol), copper(I) oxide (1.4 mg, 10
μmol), and DMSO (2 mL) to yield 2,5-di-o-tolyl-2H-tetrazole (31.4
mg, 0.13 mmol, 63% yield) as a yellow oil. 1H NMR (500 MHz,
CDCl3) δ 8.19−8.16 (m, 1H), 7.71 (d, J = 7.9 Hz, 1H), 7.49−7.34
(m, 6H), 2.72 (s, 3H), 2.47 (s, 3H). 13C{1H} NMR (126 MHz,
CDCl3) δ 165.4, 137.7, 136.7, 133.0, 132.1, 131.6, 130.3, 130.2, 129.7,
127.1, 126.4, 126.2, 125.3, 22.0, 19.1. HRMS (ESI) m/z: [M + H]+
calcd for C15H15N4 251.1291, found 251.1290. IR νmax (neat): 3063,
3032, 2961, 2924, 1607, 1584, 1520, 1495, 1476, 1452 cm−1
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